CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 59 enrolled
Drug / intervention
Somatuline Autogel (lanreotide acetate) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00447499
NCT00447499Phase 3Completed
CompareCT.gov

A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel

Ipsen·interventional·Posted Mar 14, 2007·Updated Nov 20, 2020

In Brief

A Phase 3 clinical trial evaluating Somatuline Autogel (lanreotide acetate) and Home administration for Acromegaly. Completed, enrolled 59 participants across 13 sites.

Detailed Summary

The purpose of this study is to determine whether subjects with acromegaly (or their partners) are able to self administer Somatuline Autogel at home.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcromegaly
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 14, 2007
Enrollment StartApr 1, 2007
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 19.3 years ago

Interventions

Somatuline Autogel (lanreotide acetate)drug

Injections

Home administrationbehavioral

Questionnaire